DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced that is has received the 2013
"Partnership Pioneers of the Year" award in recognition of its strategic
partnership with Pfizer and PAREXEL.
Presented by the Institute for International Research and Partnerships
in Clinical Trials' advisory board, the award recognises two or more
companies engaged in a partnership that moves beyond the traditional
transactional model to a more strategic approach that can bring
innovation to the drug development process.
ICON was selected by Pfizer in May 2011 as one of two strategic partners
for global clinical research and development. The partnership was part
of Pfizer's comprehensive program of change in R&D to sharpen research
focus, deliver differentiated innovation, and create a more flexible
cost base through external partnerships for certain R&D services.
Commenting on the award, ICON's CEO, Mr. Ciaran Murray, said: "I am
delighted that ICON has received this award which recognises our
commitment to the strategic collaboration with Pfizer. Using our scale,
clinical experience, and technology such as Firecrest, we are able to
deliver high-quality solutions for the Pfizer partnership. These
solutions help reduce cycle times and cost and improve the quality and
productivity of drug development. Over the past two years we have worked
hard with Pfizer to transform their drug development model and have
built a solid platform that will support the continued success and
evolution of the partnership in the future."
"Our new Alliance Partner Model is providing a solid foundation for
integrated quality clinical services," said Dr. John Hubbard, SVP of
Development Operations for Pfizer. "ICON and PAREXEL's
clinical expertise and innovative technology continues to set the
standard for best practice, this award recognises progress toward our
goal of creating a common culture dedicated to universally improving
clinical trial implementation. We look forward to deepening our
relationship with ICON and PAREXEL, to achieve our partnership's full
potential, and ultimately deliver medicines to patients in need more
quickly and efficiently."
Pfizer, ICON and PAREXEL accepted the honour during an awards ceremony
at the 22nd
annual Partnerships in Clinical Trials conference.
The statements made in this press release may contain forward-looking
statements that involve a number of risks and uncertainties. A
description of risks and uncertainties relating to ICON and its business
can be found in Forms 20-F for the fiscal year ended December 31st
2012 and in the other forms filed with the US Securities and Exchange
Commission, including the F-1, S-8 and F-3. ICON disclaims any intent or
obligation to update these forward-looking statements.
Notes to Editors
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has approximately 10,045
employees, operating from 79 locations in 37 countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
ICON Media Contact
Genevieve Tuck
Weber Shandwick
Tel:
+44 (0)20 7067 0655
gtuck@webershandwick.com
Source: ICON
News Provided by Acquire Media
